A Lyles

Summary

Publications

  1. doi request reprint Decision-makers' use of pharmacoeconomics: what does the research tell us?
    A Lyles
    University of Baltimore, School of Public Affairs, Health Systems Managment, 1304 St Paul St, Room 204, Baltimore, MD 21202, USA
    Expert Rev Pharmacoecon Outcomes Res 1:133-44. 2001
  2. ncbi request reprint Direct marketing of pharmaceuticals to consumers
    Alan Lyles
    Health Systems Management, University of Baltimore, Baltimore, Maryland 21202, USA
    Annu Rev Public Health 23:73-91. 2002
  3. ncbi request reprint The brief history and uncertain future of prescription drug benefits
    Alan Lyles
    Clin Ther 25:248-9. 2003
  4. ncbi request reprint Comparative information for evidence-based drug decisions
    Alan Lyles
    Clin Ther 25:2086-7. 2003
  5. ncbi request reprint Research results: balancing access with relevance for patient decisions
    Alan Lyles
    Clin Ther 25:2450-2. 2003
  6. ncbi request reprint The prescription drug user fee act: active postmarketing drug surveillance and safety
    Alan Lyles
    Clin Ther 24:800-2. 2002
  7. ncbi request reprint Evidence- or opinion-based pharmaceutical policy?
    Alan Lyles
    Clin Ther 26:1922-3. 2004
  8. ncbi request reprint Must an interest be a conflict?
    Alan Lyles
    Clin Ther 27:344-5. 2005
  9. ncbi request reprint Creating alternative incentives for pharmaceutical innovation
    Alan Lyles
    Clin Ther 28:126-8. 2006
  10. ncbi request reprint Manufacturer response to AMCP Format dossier requests
    Alan Lyles
    J Manag Care Pharm 13:290-1; author reply 291-2. 2007

Detail Information

Publications11

  1. doi request reprint Decision-makers' use of pharmacoeconomics: what does the research tell us?
    A Lyles
    University of Baltimore, School of Public Affairs, Health Systems Managment, 1304 St Paul St, Room 204, Baltimore, MD 21202, USA
    Expert Rev Pharmacoecon Outcomes Res 1:133-44. 2001
    ..performance incentives and line item budget accountability limit the usefulness of even impeccably performed pharmacoeconomic studies? Or, are methodological and logistical considerations impeding the usefulness of pharmacoeconomics?..
  2. ncbi request reprint Direct marketing of pharmaceuticals to consumers
    Alan Lyles
    Health Systems Management, University of Baltimore, Baltimore, Maryland 21202, USA
    Annu Rev Public Health 23:73-91. 2002
    ..Broadcast advertisements are too brief to include extensive technical information; consequently, the impact of FDA regulations to assure a fair balance of risk and benefit in DTCA is still being assessed...
  3. ncbi request reprint The brief history and uncertain future of prescription drug benefits
    Alan Lyles
    Clin Ther 25:248-9. 2003
  4. ncbi request reprint Comparative information for evidence-based drug decisions
    Alan Lyles
    Clin Ther 25:2086-7. 2003
  5. ncbi request reprint Research results: balancing access with relevance for patient decisions
    Alan Lyles
    Clin Ther 25:2450-2. 2003
  6. ncbi request reprint The prescription drug user fee act: active postmarketing drug surveillance and safety
    Alan Lyles
    Clin Ther 24:800-2. 2002
  7. ncbi request reprint Evidence- or opinion-based pharmaceutical policy?
    Alan Lyles
    Clin Ther 26:1922-3. 2004
  8. ncbi request reprint Must an interest be a conflict?
    Alan Lyles
    Clin Ther 27:344-5. 2005
  9. ncbi request reprint Creating alternative incentives for pharmaceutical innovation
    Alan Lyles
    Clin Ther 28:126-8. 2006
  10. ncbi request reprint Manufacturer response to AMCP Format dossier requests
    Alan Lyles
    J Manag Care Pharm 13:290-1; author reply 291-2. 2007
  11. ncbi request reprint Public-private partnerships at the National Institutes of Health: from discovery to commercialization
    Alan Lyles
    Clin Ther 25:2900-2. 2003